In a recent study conducted by Tutusaus A. et al. (2020), AXL inhibition using Bemcentinib was found to reduce lipid accumulation and overall NAFLD score, in mice fed on high fat diet [68]. Here, AXL is linked to metabolic dysfunction-associated steatotic liver disease.